Abstract
Purpose: To evaluate the outcomes of splenic artery aneurysm (SAA) embolization and compare adverse event (AE) rates after embolization in patients with and without portal hypertension (PHTN). Materials and Methods: A retrospective review of all patients who underwent embolization of SAAs at 2 institutions was performed (34 patients from institution 1 and 7 patients from institution 2). Baseline demographic characteristics, preprocedural imaging, procedural techniques, and postprocedural outcomes were evaluated. Thirty-day postprocedural severe and life-threatening AEs were evaluated using the Society of Interventional Radiology guidelines. Thirty-day mortality and readmission rates were also evaluated. t test, χ2 test, and/or Fisher exact test were used for the statistical analysis. Results: There was no statistically significant difference between patients with and without PHTN in the location, number, and size of SAA(s). All procedures were technically successful. There were 13 (32%) patients with and 28 (68%) patients without PHTN. The 30-day mortality rate (31% vs 0%; P =.007), readmission rates (61% vs 7%; P <.001), and severe/life-threatening AE rates (69% vs 0%; P <.001) were significantly higher in patients with PHTN than in those without PHTN. Conclusions: There was a significantly higher mortality and severe/life-threatening AE rate in patients with PHTN than in those without PHTN. SAAs in patients with PHTN need to be managed very cautiously, given the risk of severe/life-threatening AEs after embolization.
Original language | English (US) |
---|---|
Pages (from-to) | 1519-1526.e1 |
Journal | Journal of Vascular and Interventional Radiology |
Volume | 33 |
Issue number | 12 |
DOIs | |
State | Published - Dec 2022 |
Funding
A.R. received consulting fees from Boston Scientific. J.B. reports grants from W.L. Gore & Associates and consulting fees from W.L. Gore & Associates and Fuji Film. S.R. has received payment for numerous cases for expert review (both plaintiff and defense). D.G. has received payment or honoraria from Gilead Speaker Bureau and for participation on a Data Safety Monitoring or Advisory Board from Alexion. J.D. has received payment for Expert Witness Consulting fees, unrelated to this work, and plane, meeting registration, and lodging support for attending International Pediatric Radiology Congress October 2021. R.J.L. has received consulting fees from Boston Scientific, BD, and Varian and payments or honoraria from Boston Scientific and is a member of the Society of Interventional Radiology Executive Council. None of the other authors have identified a conflict of interest.
ASJC Scopus subject areas
- Cardiology and Cardiovascular Medicine
- Radiology Nuclear Medicine and imaging